As a result of the rights issue of common shares recently implemented by Swedish
Orphan Biovitrum, the number of shares and votes in the company has changed
during June 2011 as follows.
The number of shares has increased by 53,045,319 common shares and the total
number of shares in the company as of June 30, 2011 amounts to 267,295,132
shares, of which 265,226,598 common shares and 2,068,534 class C shares*. The
total number of votes in the company has increased by 53,045,319 and amounts to
in total 265,433,451.4 votes. The company's share capital as of June 30, 2011
amounts to approximately SEK 146,663,999.7.
For additional information, please contact:
Åsa Stenqvist, VP Communications and Investor Relations
Tel.: +46 8 697 21 88
About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading European specialty pharmaceutical company focused on providing
and developing specialty pharmaceuticals for patients with rare diseases and
significant medical needs. The portfolio comprises about 60 marketed products,
as well as projects in late clinical phase. Key therapeutic areas are
hematological diseases, autoimmune diseases, hereditary metabolic disorders and
therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 billion and
approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. For more information please visitwww.sobi.com
The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on June 30, 2011 at 8.30 CET.
*) All C-shares are held by Sobi.
[HUG#1527142]
